{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:51:07Z","timestamp":1777953067409,"version":"3.51.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.7759\/cureus.108233","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:56:09Z","timestamp":1777902969000},"source":"Crossref","is-referenced-by-count":0,"title":["Sustained Three-Year Remission Following Anti-IL-6 Therapy in a Patient With TAFRO (Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, and Organomegaly) Syndrome After Initial Misdiagnosis: A Case Report"],"prefix":"10.7759","author":[{"given":"Javier E","family":"Moyano Navarro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D","family":"Terrones Huam\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio J","family":"Barrios Aedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo F","family":"Moreno Mandarachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Pachas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02780-1","article-title":"2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome","volume":"111","author":"Masaki Y","year":"2020","unstructured":"Masaki Y, Kawabata H, Takai K, et al.. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020, 111:155-8. 10.1007\/s12185-019-02780-1","journal-title":"Int J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04762-6","article-title":"Castleman disease and TAFRO syndrome","volume":"101","author":"Masaki Y","year":"2022","unstructured":"Masaki Y, Arita K, Sakai T, Takai K, Aoki S, Kawabata H. Castleman disease and TAFRO syndrome. Ann Hematol. 2022, 101:485-90. 10.1007\/s00277-022-04762-6","journal-title":"Ann Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12051076","article-title":"Unraveling TAFRO syndrome: an in-depth look at the pathophysiology, management, and future perspectives","volume":"12","author":"Caballero JC","year":"2024","unstructured":"Caballero JC, Conejero N, Solan L, Diaz de la Pinta FJ, Cordoba R, Lopez-Garcia A. Unraveling TAFRO syndrome: an in-depth look at the pathophysiology, management, and future perspectives. Biomedicines. 2024, 12:10.3390\/biomedicines12051076","journal-title":"Biomedicines"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9622-22","article-title":"TAFRO syndrome: a disease requiring immediate medical attention","volume":"62","author":"Masaki Y","year":"2023","unstructured":"Masaki Y, Ueda Y, Yanagisawa H, et al.. TAFRO syndrome: a disease requiring immediate medical attention. Intern Med. 2023, 62:27-32. 10.2169\/internalmedicine.9622-22","journal-title":"Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25554","article-title":"Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?","volume":"94","author":"Fujimoto S","year":"2019","unstructured":"Fujimoto S, Sakai T, Kawabata H, et al.. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?. Am J Hematol. 2019, 94:975-83. 10.1002\/ajh.25554","journal-title":"Am J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-1979-1","article-title":"Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version","volume":"103","author":"Masaki Y","year":"2016","unstructured":"Masaki Y, Kawabata H, Takai K, et al.. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016, 103:686-92. 10.1007\/s12185-016-1979-1","journal-title":"Int J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-03008-3","article-title":"Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan","volume":"113","author":"Fujimoto S","year":"2021","unstructured":"Fujimoto S, Kawabata H, Sakai T, et al.. Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan. Int J Hematol. 2021, 113:73-80. 10.1007\/s12185-020-03008-3","journal-title":"Int J Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000518079","article-title":"TAFRO syndrome and elusive diagnosis of idiopathic multicentric Castleman disease treated with empiric anti-interleukin-6 therapy","volume":"14","author":"Williams C","year":"2021","unstructured":"Williams C, Phillips A, Aggarwal V, Slonim LB, Fajgenbaum DC, Karmali R. TAFRO syndrome and elusive diagnosis of idiopathic multicentric Castleman disease treated with empiric anti-interleukin-6 therapy. Case Rep Oncol. 2021, 14:1359-65. 10.1159\/000518079","journal-title":"Case Rep Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06327-9","article-title":"First-line treatment of TAFRO syndrome with rituximab: a case report and literature review","volume":"104","author":"Servati S","year":"2025","unstructured":"Servati S, Mohammadi I, Rajai Firouzabadi S. First-line treatment of TAFRO syndrome with rituximab: a case report and literature review. Ann Hematol. 2025, 104:3035-46. 10.1007\/s00277-025-06327-9","journal-title":"Ann Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.7340","article-title":"A case of TAFRO syndrome with DIC and neurologic and cardiac involvement","volume":"11","author":"Moy LN","year":"2023","unstructured":"Moy LN, Patel M, Eschbach J, Knouse P, G\u00e1lvez \u00c1. A case of TAFRO syndrome with DIC and neurologic and cardiac involvement. Clin Case Rep. 2023, 11:e07340. 10.1002\/ccr3.7340","journal-title":"Clin Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1554198","article-title":"Case report: TAFRO syndrome misdiagnosed as liver cirrhosis due to persistent abdominal distension","volume":"16","author":"Ma L","year":"2025","unstructured":"Ma L, Gu R, Ma L, et al.. Case report: TAFRO syndrome misdiagnosed as liver cirrhosis due to persistent abdominal distension. Front Immunol. 2025, 16:1554198. 10.3389\/fimmu.2025.1554198","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000039148","article-title":"Delayed diagnosis of TAFRO syndrome: a case report","volume":"103","author":"Qiao Y","year":"2024","unstructured":"Qiao Y, Zhang X, Xu R, Jia X, Wang Q. Delayed diagnosis of TAFRO syndrome: a case report. Medicine (Baltimore). 2024, 103:e39148. 10.1097\/MD.0000000000039148","journal-title":"Medicine (Baltimore)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000492743","article-title":"TAFRO syndrome with an anterior mediastinal mass and lethal autoantibody-mediated thrombocytopenia: an autopsy case report","volume":"141","author":"Morita K","year":"2019","unstructured":"Morita K, Fujiwara SI, Ikeda T, et al.. TAFRO syndrome with an anterior mediastinal mass and lethal autoantibody-mediated thrombocytopenia: an autopsy case report. Acta Haematol. 2019, 141:158-63. 10.1159\/000492743","journal-title":"Acta Haematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81952","article-title":"Survival and hospital discharge achieved through intensive circulatory, fluid, and respiratory support in severe TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) syndrome with multiorgan dysfunction: a case report","volume":"17","author":"Masui Y","year":"2025","unstructured":"Masui Y, Idei M, Yokoyama N, Yokose M, Takaki S. Survival and hospital discharge achieved through intensive circulatory, fluid, and respiratory support in severe TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) syndrome with multiorgan dysfunction: a case report. Cureus. 2025, 17:e81952. 10.7759\/cureus.81952","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/456924-sustained-three-year-remission-following-anti-il-6-therapy-in-a-patient-with-tafro-thrombocytopenia-anasarca-fever-reticulin-fibrosis-and-organomegaly-syndrome-after-initial-misdiagnosis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:56:10Z","timestamp":1777902970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/456924-sustained-three-year-remission-following-anti-il-6-therapy-in-a-patient-with-tafro-thrombocytopenia-anasarca-fever-reticulin-fibrosis-and-organomegaly-syndrome-after-initial-misdiagnosis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.108233","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,4]]}}}